Fuji Chemical Industries Announces Completion Of Construction Of High Containment Closed Spray Drying Facility
TOYAMA, JAPAN – Mr. Mitsunori Nishida, CEO of FUJI Chemical Industries Co., Ltd., has announced that its new high-containment spray dryer for drugs with high pharmacological activity drug profiles is now fully operational.
In 1999, FUJI established commercial manufacturing technology with a closed spray dryer (CSD) and has since received a significant number of orders from major international and domestic pharmaceutical companies. Continued growth necessitated the need for the second facility “2CSD” (High Containment Spray Dryer), which was built and became operational in the summer of 2015. “In addition to this, we are anticipating further needs of our customers for anti-cancer drugs for aging populations, and we have therefore installed a new High Containment Spray Drying facility to accommodate these and future needs,” Mr. Nishida stated.
Recently, he added, scientific studies have emphasized the importance of developing oral medications that have improved absorption characteristics in the gastrointestinal tract.
This trend is particularly evident in new drugs with high pharmacological activity profiles that deliver high pharmacologic effects in small doses. Accordingly, the demand for High Containment CSD’s is increasing since this manufacturing process improves systemic absorption of newer drugs in the gastrointestinal tract. FUJI’s new facility is a high-containment system, which is compliant with the Chemical Hazardous Act, enabling FUJI to provide service to a variety of customer needs. “FUJI can now expand its business with new drug manufacturers worldwide (USA, EU, Japan, etc.) through our continuous production CSD process for high potency drugs,” Mr. Nishida asserted. “FUJI can provide customers with all their spray drying requirements including high potency drug processing solutions.”
About Fuji Chemical Industries, Co. Ltd.
Fuji Chemical Industries Co., Ltd. is engaged in the production and sale of pharmaceutical products/synthesis, the manufacture of pharmaceutical and bulk pharmaceutical products, and the production and sale of food additives. It offers contract manufacturing services that include API manufacturing; functional APIs, such as drug intermediates; and drug products manufacturing. The company also provides excipients and drug delivery systems.
In 1999, FUJI established commercial manufacturing technology with a closed spray dryer (CSD) and has since received a significant number of orders from major international and domestic pharmaceutical companies. Continued growth necessitated the need for the second facility “2CSD” (High Containment Spray Dryer), which was built and became operational in the summer of 2015. “In addition to this, we are anticipating further needs of our customers for anti-cancer drugs for aging populations, and we have therefore installed a new High Containment Spray Drying facility to accommodate these and future needs,” Mr. Nishida stated.
Recently, he added, scientific studies have emphasized the importance of developing oral medications that have improved absorption characteristics in the gastrointestinal tract.
This trend is particularly evident in new drugs with high pharmacological activity profiles that deliver high pharmacologic effects in small doses. Accordingly, the demand for High Containment CSD’s is increasing since this manufacturing process improves systemic absorption of newer drugs in the gastrointestinal tract. FUJI’s new facility is a high-containment system, which is compliant with the Chemical Hazardous Act, enabling FUJI to provide service to a variety of customer needs. “FUJI can now expand its business with new drug manufacturers worldwide (USA, EU, Japan, etc.) through our continuous production CSD process for high potency drugs,” Mr. Nishida asserted. “FUJI can provide customers with all their spray drying requirements including high potency drug processing solutions.”
About Fuji Chemical Industries, Co. Ltd.
Fuji Chemical Industries Co., Ltd. is engaged in the production and sale of pharmaceutical products/synthesis, the manufacture of pharmaceutical and bulk pharmaceutical products, and the production and sale of food additives. It offers contract manufacturing services that include API manufacturing; functional APIs, such as drug intermediates; and drug products manufacturing. The company also provides excipients and drug delivery systems.